6,678 trials
Lumbar Spinal Stenosis
Primary: Mean Change in VAS — 2.52; 0.06 units on a scale — p=<0.05
Tobacco Use Disorder
Primary: Smoking Abstinence — 41; 18; 33; 19 percentage of participants — p=0.001
Chronic Obstructive Pulmonary Disease
Primary: Unpleasantness of Breathlessness — 72.5; 72.6 units on a scale
Erectile Dysfunction
Primary: Percentage of Participants With a Score of Greater Than or Equal to 22 in the Erectile Function (EF) Domain of the International Index of Erectile Function (IIEF)…
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 104 or Last Reported Visit (LRV) — 80.6; 79.7; -18.1; -17.7 Units on a scale
Chronic Hepatitis C
Primary: Change in Hepatitis C Virus RNA Levels During Phase I — 0.50; 0.70 log(IU/mL) — p=0.54
Impaired Glucose Tolerance
Primary: Change in Reactive Hyperemic Index Over the 3-month Treatment Period — 0.01; -0.17 ratio
HIV Infections · Cytomegalovirus Infections
Primary: Change in %CD38+ Human Leukocyte Antigen-D-related (HLA-DR)+ CD8+ T Cells From Baseline to Week 8. — 1.3; -4.0 percentage of activated T cells
Hunter Syndrome · Mucopolysaccharidosis II · MPS II
Primary: Safety Evaluation — 28; 0; 0; 16 participants
Psoriasis
Primary: Percentage Change From Baseline in Psoriasis Scalp Severity Index at Week 12 — 20.4; 86.8 Percent change — p=<0.0001
Intraventricular Hemorrhage · Subarachnoid Hemorrhage
Primary: Number of Infections — 4; 5; 4; 5 Infections
Influenza
Primary: Number of Participants Reporting Solicited Injection Site and Systemic Reactions Following Vaccination With Fluzone® or Fluzone® Intradermal or Fluzone® High-Dose…
Dental Caries
Primary: Percentage Surface Microhardness Recovery (%SMHR) of Enamel Specimens Exposed to NaF Toothpaste (1450ppmF) and SnF/NaF Toothpaste (1450ppmF) — 40.94; 17.88 Percentage of…
Neoplasms, Prostate
Primary: Time to Disease Progression — 376.9; 433.1 Days — p=0.79
Non ST Elevation Myocardial Infarction
Primary: Major Adverse Cardiac and Cerebrovascular Events (MACCE) — 35.3; 13.8 Percentage of study group